lenvatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 4942 417716-92-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • E-7080
  • E 7080
  • lenvatinib
  • lenvima
  • ER-203492-00
  • E7080
  • lenvatinib mesylate
  • lenvatinib mesilate
a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)
  • Molecular weight: 426.86
  • Formula: C21H19ClN4O4
  • CLOGP: 3.05
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 3
  • TPSA: 115.57
  • ALOGS: -4.84
  • ROTB: 6

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
18 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 26, 2015 PMDA Eisai Co., Ltd.
Feb. 13, 2015 FDA EISAI INC
May 28, 2015 EMA Eisai Europe Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypertension 829.31 24.54 512 9391 210691 50384530
Malignant neoplasm progression 744.18 24.54 329 9574 67795 50527426
Proteinuria 527.43 24.54 175 9728 16422 50578799
Decreased appetite 387.91 24.54 317 9586 200606 50394615
Palmar-plantar erythrodysaesthesia syndrome 319.00 24.54 127 9776 19971 50575250
Hepatic encephalopathy 237.14 24.54 84 9819 9552 50585669
Diarrhoea 197.35 24.54 384 9519 588092 50007129
Platelet count decreased 152.94 24.54 139 9764 100587 50494634
Blood pressure increased 151.92 24.54 157 9746 132975 50462246
Hypothyroidism 130.61 24.54 82 9821 34043 50561178
Cholecystitis 98.50 24.54 50 9853 13821 50581400
Drug ineffective 95.62 24.54 22 9881 819311 49775910
Stomatitis 90.20 24.54 105 9798 101239 50493982
Tumour haemorrhage 88.95 24.54 25 9878 1330 50593891
Tracheal fistula 67.95 24.54 11 9892 32 50595189
Fatigue 67.84 24.54 295 9608 707306 49887915
Pneumothorax 67.29 24.54 39 9864 13995 50581226
Fistula 62.38 24.54 31 9872 8187 50587034
Dysphonia 61.50 24.54 55 9848 38837 50556384
Oral pain 51.07 24.54 41 9862 24992 50570229
Gastrointestinal perforation 50.78 24.54 20 9883 3041 50592180
Dehydration 48.63 24.54 98 9805 152351 50442870
Nephrotic syndrome 48.47 24.54 22 9881 4748 50590473
Arterial haemorrhage 47.69 24.54 16 9887 1541 50593680
Ascites 47.58 24.54 46 9857 35815 50559406
Blood thyroid stimulating hormone increased 46.29 24.54 23 9880 6069 50589152
Protein urine present 45.96 24.54 22 9881 5355 50589866
Condition aggravated 43.58 24.54 4 9899 297054 50298167
Weight decreased 40.90 24.54 115 9788 221130 50374091
Posterior reversible encephalopathy syndrome 40.52 24.54 29 9874 14899 50580322
Cerebral haemorrhage 40.29 24.54 37 9866 27015 50568206
Hepatic function abnormal 37.96 24.54 39 9864 32642 50562579
Vomiting 37.86 24.54 184 9719 460574 50134647
Malaise 37.47 24.54 147 9756 335385 50259836
Cholecystitis acute 37.42 24.54 21 9882 7085 50588136
Drug hypersensitivity 35.19 24.54 4 9899 251006 50344215
Epistaxis 34.66 24.54 52 9851 63902 50531319
Colitis 34.34 24.54 40 9863 38489 50556732
Oesophageal fistula 32.35 24.54 7 9896 123 50595098
Intestinal perforation 32.27 24.54 22 9881 10457 50584764
Thrombocytopenia 31.46 24.54 74 9829 127599 50467622
Tracheal haemorrhage 31.45 24.54 7 9896 141 50595080
Primary adrenal insufficiency 31.33 24.54 6 9897 55 50595166
Hypersensitivity 31.26 24.54 3 9900 215158 50380063
Immune-mediated hepatitis 30.53 24.54 10 9893 894 50594327
Hypertensive crisis 29.97 24.54 23 9880 13131 50582090
Nausea 28.01 24.54 234 9669 705164 49890057
Oesophageal perforation 27.24 24.54 7 9896 264 50594957
Weight increased 26.41 24.54 4 9899 201887 50393334
Ammonia increased 26.40 24.54 14 9889 4227 50590994
Swelling 26.23 24.54 4 9899 200868 50394353
Large intestine perforation 26.13 24.54 17 9886 7477 50587744
Oesophageal varices haemorrhage 25.40 24.54 9 9894 1021 50594200
Product use in unapproved indication 25.19 24.54 64 9839 115755 50479466
Off label use 24.86 24.54 34 9869 474392 50120829

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Decreased appetite 715.98 23.45 562 12896 144780 29416289
Hepatic encephalopathy 708.52 23.45 254 13204 12781 29548288
Malignant neoplasm progression 692.71 23.45 425 13033 73434 29487635
Proteinuria 510.70 23.45 211 13247 15593 29545476
Palmar-plantar erythrodysaesthesia syndrome 473.28 23.45 196 13262 14563 29546506
Hypertension 451.31 23.45 393 13065 116221 29444848
Diarrhoea 351.90 23.45 576 12882 332122 29228947
Hypothyroidism 233.18 23.45 123 13335 15783 29545286
Tumour haemorrhage 199.63 23.45 65 13393 2420 29558649
Liver carcinoma ruptured 174.05 23.45 34 13424 131 29560938
Fatigue 165.36 23.45 410 13048 316411 29244658
Blood pressure increased 143.25 23.45 172 13286 73631 29487438
Dysphonia 140.73 23.45 95 13363 19101 29541968
Ascites 114.59 23.45 110 13348 36509 29524560
Malaise 112.20 23.45 233 13225 159369 29401700
Oesophageal varices haemorrhage 111.14 23.45 43 13415 2659 29558410
Hepatic failure 97.32 23.45 94 13364 31418 29529651
Drug ineffective 95.70 23.45 24 13434 363146 29197923
Ammonia increased 88.27 23.45 41 13417 3990 29557079
Stomatitis 82.76 23.45 93 13365 37020 29524049
Cholecystitis 78.29 23.45 50 13408 9147 29551922
Pneumothorax 72.34 23.45 59 13399 15783 29545286
Blood bilirubin increased 70.60 23.45 82 13376 33811 29527258
Cholangitis 69.22 23.45 43 13415 7494 29553575
Oral pain 65.64 23.45 45 13413 9262 29551807
Dehydration 61.93 23.45 151 13307 114597 29446472
Hepatic function abnormal 60.98 23.45 82 13376 39177 29521892
Blood thyroid stimulating hormone increased 60.07 23.45 29 13429 3076 29557993
Tumour rupture 55.66 23.45 14 13444 200 29560869
Epistaxis 51.77 23.45 88 13370 51616 29509453
Drug interaction 48.18 23.45 15 13443 197370 29363699
Weight decreased 47.78 23.45 164 13294 150741 29410328
Toxicity to various agents 46.51 23.45 11 13447 173650 29387419
Tracheal fistula 45.83 23.45 10 13448 73 29560996
Portal vein thrombosis 43.98 23.45 24 13434 3285 29557784
Condition aggravated 43.94 23.45 7 13451 146288 29414781
Hyperammonaemia 43.80 23.45 29 13429 5634 29555435
Platelet count decreased 40.58 23.45 122 13336 104550 29456519
Off label use 37.83 23.45 49 13409 300751 29260318
Vomiting 36.84 23.45 192 13266 212068 29349001
Taste disorder 35.83 23.45 24 13434 4752 29556317
Cholecystitis acute 35.81 23.45 25 13433 5294 29555775
Gastrointestinal perforation 34.86 23.45 21 13437 3462 29557607
Thyroiditis 34.28 23.45 17 13441 1911 29559158
Tracheo-oesophageal fistula 33.52 23.45 11 13447 419 29560650
Immune-mediated hepatitis 31.78 23.45 15 13443 1512 29559557
Liver abscess 30.53 23.45 19 13439 3319 29557750
Neutropenia 30.38 23.45 11 13447 131700 29429369
Rhythm idioventricular 29.39 23.45 9 13449 273 29560796
Protein urine present 29.15 23.45 21 13437 4673 29556396
Liver disorder 26.14 23.45 46 13412 27703 29533366
Nausea 25.98 23.45 222 13236 289033 29272036
Protein induced by vitamin K absence or antagonist II increased 25.86 23.45 5 13453 18 29561051
Haemobilia 24.50 23.45 8 13450 300 29560769
Arterial haemorrhage 24.20 23.45 10 13448 734 29560335
Nephrotic syndrome 23.62 23.45 21 13437 6307 29554762

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 1170.76 22.09 574 16205 112297 64369656
Hypertension 1026.93 22.09 704 16075 258557 64223396
Proteinuria 843.20 22.09 304 16475 27419 64454534
Decreased appetite 748.29 22.09 602 16177 280687 64201266
Hepatic encephalopathy 662.85 22.09 237 16542 20829 64461124
Palmar-plantar erythrodysaesthesia syndrome 611.45 22.09 243 16536 28576 64453377
Diarrhoea 315.93 22.09 622 16157 722082 63759871
Tumour haemorrhage 270.38 22.09 78 16701 3415 64478538
Hypothyroidism 267.67 22.09 153 16626 40304 64441649
Drug ineffective 156.85 22.09 18 16761 840229 63641724
Pneumothorax 152.91 22.09 89 16690 24209 64457744
Cholecystitis 145.37 22.09 80 16699 19556 64462397
Liver carcinoma ruptured 139.55 22.09 26 16753 146 64481807
Platelet count decreased 135.30 22.09 191 16588 167520 64314433
Ascites 127.32 22.09 115 16664 61886 64420067
Oesophageal varices haemorrhage 110.85 22.09 40 16739 3589 64478364
Blood pressure increased 108.50 22.09 175 16604 172377 64309576
Tracheal fistula 102.86 22.09 19 16760 101 64481852
Malaise 98.82 22.09 275 16504 395972 64085981
Dysphonia 93.17 22.09 85 16694 46297 64435656
Hepatic function abnormal 90.40 22.09 97 16682 64216 64417737
Blood bilirubin increased 86.57 22.09 90 16689 57463 64424490
Dehydration 78.86 22.09 174 16605 216589 64265364
Blood thyroid stimulating hormone increased 76.09 22.09 38 16741 7616 64474337
Cholecystitis acute 75.14 22.09 43 16736 11317 64470636
Tracheo-oesophageal fistula 70.15 22.09 18 16761 503 64481450
Hepatic failure 69.95 22.09 79 16700 55315 64426638
Arterial haemorrhage 69.67 22.09 25 16754 2206 64479747
Nephrotic syndrome 68.11 22.09 38 16741 9529 64472424
Toxicity to various agents 67.03 22.09 8 16771 363505 64118448
Condition aggravated 66.73 22.09 9 16770 372417 64109536
Fistula 64.70 22.09 37 16742 9724 64472229
Stomatitis 64.53 22.09 108 16671 109497 64372456
Fatigue 63.12 22.09 370 16409 748360 63733593
Ammonia increased 61.67 22.09 32 16747 6945 64475008
Gastrointestinal perforation 60.10 22.09 29 16750 5395 64476558
Immune-mediated hepatitis 59.78 22.09 23 16756 2466 64479487
Cholangitis 58.65 22.09 36 16743 10766 64471187
Hyperammonaemia 51.22 22.09 32 16747 9872 64472081
Portal vein thrombosis 50.26 22.09 25 16754 4966 64476987
Cerebral haemorrhage 49.96 22.09 64 16715 51026 64430927
Vomiting 47.35 22.09 274 16505 550843 63931110
Primary adrenal insufficiency 44.20 22.09 9 16770 85 64481868
Posterior reversible encephalopathy syndrome 44.01 22.09 41 16738 22905 64459048
Protein urine present 43.97 22.09 28 16751 8928 64473025
Hypertensive crisis 43.75 22.09 37 16742 18211 64463742
Drug interaction 43.37 22.09 20 16759 362063 64119890
Large intestine perforation 41.94 22.09 31 16748 12573 64469380
Epistaxis 41.68 22.09 84 16695 98047 64383906
Weight decreased 41.15 22.09 165 16614 285574 64196379
Haemoptysis 41.13 22.09 57 16722 48991 64432962
Weight increased 41.06 22.09 4 16775 213344 64268609
Hypersensitivity 39.67 22.09 3 16776 196449 64285504
Intestinal perforation 38.68 22.09 32 16747 15281 64466672
Drug hypersensitivity 37.59 22.09 8 16771 237807 64244146
Off label use 36.78 22.09 68 16711 632738 63849215
Tumour rupture 36.78 22.09 10 16769 351 64481602
Pneumonitis 34.22 22.09 53 16726 50312 64431641
Fall 34.02 22.09 35 16744 416791 64065162
Tumour lysis syndrome 33.98 22.09 33 16746 19407 64462546
Oesophageal perforation 33.77 22.09 12 16767 1029 64480924
Oesophageal fistula 33.49 22.09 9 16770 302 64481651
Cerebral infarction 33.37 22.09 47 16732 40997 64440956
Thyroiditis 33.12 22.09 17 16762 3607 64478346
Upper gastrointestinal haemorrhage 32.68 22.09 43 16736 35177 64446776
Drug intolerance 32.56 22.09 5 16774 187987 64293966
Pyrexia 32.38 22.09 252 16527 558392 63923561
Colitis 32.11 22.09 56 16723 58618 64423335
Product dose omission issue 29.86 22.09 7 16772 194740 64287213
Liver disorder 29.29 22.09 51 16728 53300 64428653
Pulmonary embolism 29.12 22.09 94 16685 146262 64335691
Rhythm idioventricular 28.87 22.09 9 16770 514 64481439
Cardiac failure 28.15 22.09 87 16692 132286 64349667
Oral pain 27.75 22.09 35 16744 27458 64454495
Sinusitis 27.39 22.09 3 16776 145925 64336028
Adrenal insufficiency 26.56 22.09 31 16748 22456 64459497
Abdominal pain 26.52 22.09 155 16624 312220 64169733
Interstitial lung disease 26.38 22.09 70 16709 97662 64384291
Small intestinal perforation 26.20 22.09 13 16766 2567 64479386
Overdose 25.97 22.09 5 16774 159561 64322392
Pancreatitis 25.26 22.09 51 16728 59556 64422397
Pain 25.15 22.09 68 16711 553443 63928510
Hyponatraemia 24.88 22.09 90 16689 148249 64333704
Liver abscess 24.66 22.09 16 16763 5264 64476689
Cholangitis acute 24.45 22.09 10 16769 1258 64480695
Renal impairment 24.44 22.09 84 16695 134933 64347020
Tracheal haemorrhage 23.57 22.09 8 16771 598 64481355
Hyperthyroidism 23.06 22.09 26 16753 18153 64463800
Cancer pain 22.63 22.09 14 16765 4243 64477710

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EX08 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000020000 Receptor Tyrosine Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:62434 ALK inhibitor
CHEBI has role CHEBI:63457 FGFR inhibitors
CHEBI has role CHEBI:65207 vascular endothelial growth factor receptor inhibitors
CHEBI has role CHEBI:71031 orphan drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Endometrial carcinoma progressing after chemotherapy indication 254878006 DOID:2871
Follicular thyroid carcinoma indication 255028004 DOID:3962
Papillary thyroid carcinoma indication 255029007 DOID:3969
Renal cell carcinoma indication 702391001 DOID:4450
Thymic carcinoma indication 722670005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.09 acidic
pKa2 12.74 acidic
pKa3 13.02 acidic
pKa4 4.67 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL 9006256 July 27, 2027 METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL 9006256 July 27, 2027 METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Feb. 13, 2022 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Feb. 13, 2022 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Sept. 17, 2022 TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Sept. 17, 2022 TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL July 21, 2024 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL July 21, 2024 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Aug. 10, 2024 LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Aug. 10, 2024 LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Dec. 19, 2024 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Dec. 19, 2024 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1
EQ 10MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Aug. 15, 2025 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
EQ 4MG BASE LENVIMA EISAI INC N206947 Feb. 13, 2015 RX CAPSULE ORAL Aug. 15, 2025 INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase INHIBITOR Ki 8.82 CHEMBL DRUG LABEL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR IC50 7 SCIENTIFIC LITERATURE DRUG LABEL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR IC50 7.66 SCIENTIFIC LITERATURE DRUG LABEL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR IC50 8.40 SCIENTIFIC LITERATURE DRUG LABEL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR IC50 8.28 SCIENTIFIC LITERATURE DRUG LABEL
Platelet-derived growth factor receptor alpha Kinase INHIBITOR IC50 7.29 SCIENTIFIC LITERATURE DRUG LABEL
Fibroblast growth factor receptor 1 Kinase INHIBITOR IC50 7.34 SCIENTIFIC LITERATURE DRUG LABEL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 5.51 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 7.96 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 5.41 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 7.34 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 6.76 CHEMBL
MAP kinase-activated protein kinase 2 Kinase Kd 7.20 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 6.66 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme Kd 5.82 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 6.24 CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1 Kinase Kd 5.65 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 5.54 CHEMBL
Ferrochelatase, mitochondrial Enzyme Kd 5.55 CHEMBL
Receptor-interacting serine/threonine-protein kinase 3 Kinase Kd 6.50 CHEMBL
Mitogen-activated protein kinase kinase kinase 6 Kinase Kd 5.80 CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR IC50 7.41 SCIENTIFIC LITERATURE
Epidermal growth factor receptor Kinase INHIBITOR IC50 5.19 SCIENTIFIC LITERATURE
Aurora kinase B Kinase Kd 5.75 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 5.42 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.88 CHEMBL
Breakpoint cluster region protein Kinase Kd 5.39 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 6.10 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 6.25 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 6.66 CHEMBL

External reference:

IDSource
EE083865G2 UNII
D09919 KEGG_DRUG
4034239 VUID
N0000191429 NUI
857890-39-2 SECONDARY_CAS_RN
4034239 VANDF
C2986924 UMLSCUI
CHEBI:85994 CHEBI
LEV PDB_CHEM_ID
CHEMBL1289601 ChEMBL_ID
9823820 PUBCHEM_CID
DB09078 DRUGBANK_ID
CHEMBL2105704 ChEMBL_ID
9361 INN_ID
C531958 MESH_SUPPLEMENTAL_RECORD_UI
7426 IUPHAR_LIGAND_ID
1603296 RXNORM
232716 MMSL
294829 MMSL
294831 MMSL
30895 MMSL
d08346 MMSL
714108002 SNOMEDCT_US
714109005 SNOMEDCT_US
735068004 SNOMEDCT_US
015899 NDDF
015900 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-704 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-704 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-708 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-708 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-710 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-710 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-712 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-712 CAPSULE 4 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-720 CAPSULE 10 mg ORAL NDA 32 sections
Lenvima HUMAN PRESCRIPTION DRUG LABEL 1 62856-720 CAPSULE 10 mg ORAL NDA 32 sections